ERBB2 and metabolic syndrome: Similarly, pooled data from four cohort studies (n ≈ 6800) showed that metabolic syndrome nearly doubled the risk of early biomarker-defined cardiotoxicity—including rises in high-sensitivity troponin and natriuretic peptides—during treatment with anthracyclines or HER2-targeted agents [28].